9MW3811

News alerts, weekly reports and conference planners

Company:

Calico Life Sciences, Mabwell (Shanghai) Biosci

Drug class:

IL-11 inhibitor

‹

›

3ms

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects (clinicaltrials.gov)

P1, N=32, Completed, Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting --> Completed

3 months ago

Trial completion • First-in-human

9MW3811

10ms

IL-11/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade. (PubMed, NPJ Precis Oncol)

Furthermore, 9MW3811 counteracts PD-1-induced T cell exhaustion, with anti-PD-1 antibodies effectively mitigating PD-1 upregulation post-9MW3811 treatment. These compelling findings support ongoing clinical trials of 9MW3811, aiming to translate these preclinical insights into therapeutic benefits for cancer patients.

10 months ago

Journal

CD8 (cluster of differentiation 8)

9MW3811

over2years

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=27, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.

over 2 years ago

New P1 trial • Metastases

9MW3811